NovelStem International Corp. (NSTM)
0.0095
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
NovelStem International Research and Development Expense (Quarterly)
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2013 | 0.00 |
| June 30, 2013 | |
| March 31, 2013 | 0.0575M |
| December 31, 2012 | 0.2484M |
| September 30, 2012 | 0.1087M |
| June 30, 2012 | 0.1577M |
| March 31, 2012 | |
| December 31, 2011 | 0.4207M |
| September 30, 2011 | 0.5192M |
| June 30, 2011 | 0.779M |
| March 31, 2011 | 0.6264M |
| December 31, 2010 | 0.6567M |
| September 30, 2010 | 0.6444M |
| June 30, 2010 | 0.6406M |
| March 31, 2010 | 0.6892M |
| December 31, 2009 | 0.6251M |
| September 30, 2009 | 0.7073M |
| June 30, 2009 | 0.5949M |
| March 31, 2009 | 0.642M |
| December 31, 2008 | |
| September 30, 2008 | 0.7837M |
| June 30, 2008 | 1.567M |
| March 31, 2008 | 1.760M |
| December 31, 2007 | 1.691M |
| September 30, 2007 | 1.588M |
| Date | Value |
|---|---|
| June 30, 2007 | 2.038M |
| March 31, 2007 | 1.956M |
| December 31, 2006 | 2.026M |
| September 30, 2006 | 1.818M |
| June 30, 2006 | 1.675M |
| March 31, 2006 | 1.971M |
| December 31, 2005 | 1.698M |
| September 30, 2005 | 1.478M |
| June 30, 2005 | 1.365M |
| March 31, 2005 | 1.345M |
| December 31, 2004 | |
| September 30, 2004 | |
| June 30, 2004 | |
| March 31, 2004 | |
| December 31, 2003 | 1.518M |
| September 30, 2003 | |
| June 30, 2003 | |
| March 31, 2003 | |
| December 31, 2002 | |
| September 30, 2002 | |
| June 30, 2002 | |
| March 31, 2002 | |
| December 31, 2001 | |
| September 30, 2001 | |
| June 30, 2001 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Brainstorm Cell Therapeutics, Inc. | 0.917M |
| Summit Therapeutics, Inc. | 157.73M |
| Kezar Life Sciences, Inc. | 1.545M |
| Protara Therapeutics, Inc. | 16.88M |
| Clene, Inc. | 3.135M |